EECP/ECP for Stable and Unstable Angina
-
Price:
Negotiable
- minimum:
- Total supply:
-
Delivery term:
The date of payment from buyers deliver within days
-
seat:
Chongqing
-
Validity to:
Long-term effective
-
Last update:
2021-09-06 08:03
-
Browse the number:
167
+
- Contactaixin:
psk888(Mr.)
-
Email:
telephone:
phone:
-
Arrea:
Chongqing
Address:4th Floor, 4th Building, Gangcheng Donghuan Road, No. 5, Jiangbei District, 400026, Chongqing, China
- Website:
+
Our meta-analysis suggested that 85% of the patients those underwent EECP therapy improved by at least 1 CCS class immediately post-EECP treatment. The CCS angina class is a relatively minor predictor of prognosis and freedom from events, so our results are noteworthy and the studies evaluated long-term benefit of EECP therapy are warranted. Currently, EECP treatment provides a safe, well-tolerated, valuable option for patients who were unresponsive to maximal medical management and/or invasive therapy. Of note, in combination with other antianginal drugs, the FDA approved Ranolazine to treatment for chronic angina in 2002.
Operation Environment
Ambient temperature: 10°C~30°C;
Relative humidity: less than 85%;
Atmospheric pressure (absolute pressure): 70kPa~106kPa;
Well ventilated and free of dust, corrosive gases and strong electromagnetic interference.
http://www.cneecp.com/
